GSTM1 and tuberculosis: The patients who received luspatercept as the second line after ESA were 259, and their ORR was 51.3% (133/259): 45.1% (60/133) of patients obtained TI with Hb increase ≥1.5 g/dL, 36.8% (49/133) achieved RBC‐TI without experiencing Hb increase >1.5 g/dL, 18% (24/133) exhibited a reduction >50% in TB.